remove_red_eye 523 Views
#Diabetes and Endocrinology #Internal Medicine #Pathology and Lab Medicine #Pharmacist
Adding a glucagon-like peptide-1 (GLP-1) receptor agonist to a dual-specificity tyrosine-regulated kinase 1A (DYRK1A) inhibitor induced a 5% to 6% increase in human beta-cell replication in the laboratory, reported a study published online in Science Translational Medicine.
Researchers obtained human islet cells from 111 cadaveric donors who were not diabetic and 11 cadaveric donors who had type 2 diabetes. They assessed whether adding a GLP-1 receptor agonist to a DYRK1A inhibitor would synergistically induce adult human cadaveric beta-cells to replicate in cell cultures. 10 µM harmine was combined with a range of doses of GLP-1 and a dose-related, progressive increase in proliferation of beta-cells was noted. Researchers noted high replication rates of 5% to 8% a day, some as high as 20%.